Reproductive biomedicine online · 2026
NR5A2 increases inflammation and cell proliferation by regulating the nuclear factor κB pathway in polyendocrine metabolic ovarian syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Ruiqiong, Wang Zhaoyi, Dong Mei, Wang Songlu, Huang Li, Wang Jiao, Zhang Xiqian, Liu Fenghua
Аннотация
RESEARCH QUESTION: Does NR5A2 (nuclear receptor subfamily 5 group A member 2) play a role in the dysregulation of granulosa cells in polyendocrine metabolic ovarian syndrome (PMOS), which is a common endocrine disorder and a leading cause of anovulatory infertility, and what are its underlying regulatory mechanisms?
DESIGN: The mRNA expression levels of NR5A2 and related genes were assessed in human granulosa cells (HGCs) isolated from patients with or without PMOS. To investigate the effects of NR5A2 on inflammation and proliferation of granulosa cells, as well as the underlying molecular mechanisms, in-vitro experiments were conducted using the KGN human granulosa-like cell line.
RESULTS: Overexpression of NR5A2 promoted cell proliferation and induced G1-to-S phase transition in KGN cells, at least in part by upregulating cyclin D1 (CCND1) expression. NR5A2 acted as a co-activator of NF-κB p65 (also known as RelA) by increasing its phosphorylation and nuclear localization, thereby increasing CCND1 expression through transcriptional regulation. Furthermore, NR5A2 regulated the IL-1β positive self-regulatory loop via the NF-κB p65 signalling pathway.
CONCLUSIONS: Up-regulated NR5A2 may contribute to chronic inflammation and aberrant proliferation of granulosa cells by increasing NF-κB p65 activity. These findings highlight NR5A2 as a potential therapeutic target for ameliorating ovarian dysfunction in patients with PMOS.
DESIGN: The mRNA expression levels of NR5A2 and related genes were assessed in human granulosa cells (HGCs) isolated from patients with or without PMOS. To investigate the effects of NR5A2 on inflammation and proliferation of granulosa cells, as well as the underlying molecular mechanisms, in-vitro experiments were conducted using the KGN human granulosa-like cell line.
RESULTS: Overexpression of NR5A2 promoted cell proliferation and induced G1-to-S phase transition in KGN cells, at least in part by upregulating cyclin D1 (CCND1) expression. NR5A2 acted as a co-activator of NF-κB p65 (also known as RelA) by increasing its phosphorylation and nuclear localization, thereby increasing CCND1 expression through transcriptional regulation. Furthermore, NR5A2 regulated the IL-1β positive self-regulatory loop via the NF-κB p65 signalling pathway.
CONCLUSIONS: Up-regulated NR5A2 may contribute to chronic inflammation and aberrant proliferation of granulosa cells by increasing NF-κB p65 activity. These findings highlight NR5A2 as a potential therapeutic target for ameliorating ovarian dysfunction in patients with PMOS.